



**MaineCare Services**  
An Office of the  
Department of Health and Human Services

John E. Baldacci, Governor

Brenda M. Harvey, Commissioner

Department of Health and Human Services  
MaineCare Services  
442 Civic Center Drive  
# 11 State House Station  
Augusta, Maine 04333-0011  
Tel: (207) 287-2674; Fax: (207) 287-2675  
TTY: 1-800-423-4331

**To:** MaineCare Providers  
**From:** Jennifer Palow, Pharmacy Unit Manager  
**Date:** July 26th, 2010  
**Re:** Major PDL changes due to Healthcare Reform

The recent Healthcare Reform (HCR) Act will change the way certain medications are viewed by the Federal Government as product extensions of the original product. Some extended release or strength versions of current drug products will now be affected more greatly under the Federal Rebate program and cause a negative impact on the MaineCare pharmacy budget. These changes in HCR will bring multiple changes to the MaineCare Preferred Drug List. MaineCare, with input from the DUR committee, has decided to remove the following medications from the preferred status effective July 30th, 2010 while those in bold print will be allowed for current members until 10/1/10 for certain indications, please see below.

**Seroquel XR**  
**Tegretol XR**  
Detrol LA Cap  
**Focalin XR Cap**

Sanctura XR  
Maxalt MLT  
Lescol XL  
**Keppra XR Tab**

- Detrol LA- Providers will need to transition to regular Detrol or other preferred antispasmodic bladder agents.
- Focalin XR- Providers will need to transition to other preferred agents, while current users will be allowed to continue getting the Focalin XR until 10/1/10.
- Keppra XR- Providers will need to transition to other preferred agents, while current seizure users will be allowed to continue getting the Keppra XR.
- Maxalt MLT- Providers will need to transition new and current users to the preferred triptan which is generic sumatriptan.
- Tegretol XR- Providers will need to transition to other preferred agents, while current seizure users will be allowed to continue getting the Tegretol XR.
- Lescol XL- Providers will need to transition to other preferred products
- Seroquel XR- Providers will need to transition to regular Seroquel or other preferred products. Current users with diagnosis of schizophrenia, bipolar disorder or autism will be allowed to continue getting Seroquel XR until 10/1/10.

If you have any questions you may contact Goold Health System at 1-888-445-0497 or Jennifer Palow at [Jennifer.Palow@maine.gov](mailto:Jennifer.Palow@maine.gov)

*Caring. Responsive. Well-Managed. We are DHHS.*